Researchers Uncover How MN1 Overexpression Causes AML

Published on in CHOP News

Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a mystery.

“Looking at the sequence, the protein has no obvious structure,” said Kathrin M. Bernt, MD, a pediatric oncologist in the Cancer Center’s Leukemia and Lymphoma Program at Children’s Hospital of Philadelphia (CHOP). “MN1 doesn’t resemble other typical oncogenes – or any other proteins – so it’s difficult to ascertain its function.”

Kathrin M. Bernt, MD Kathrin M. Bernt, MD To better understand how MN1 overexpression causes AML, Bernt and her colleagues decided to figure out what proteins MN1 interacts with, which would help them uncover the chain of events that ultimately leads to uncontrolled cell growth. Using a proteomics approach, the researchers identified the BAF complex – a site crucial for the regulation of gene expression and differentiation that is mutated in about 20% of cancers – as the main interaction partner of oncogenic MN1.

BAF is critical in reading DNA, interacting with regulatory regions that govern how much of a gene is expressed. The researchers found that overexpression of MN1 strengthens the BAF complex’s interaction with DNA, which has direct consequences for blood cell production. Bone marrow regularly produces progenitor and hematopoietic stem cells that eventually become mature blood cells. For that to happen, the cells need to turn off early programs that allow them to wildly proliferate and turn on programs that tell them what kind of cell to be. To shut down those early programs, promoters and regulatory regions need to be silenced, but when MN1 is overexpressed, it keeps reinforcing the interaction between BAF and DNA, which encourages the overproduction in the bone marrow of unwanted progenitor cells.

The researchers also found that the ability of MN1 to stabilize the BAF complex is dependent on a part of the MN1 protein structure known as the polyQ-stretch. Like protein “glue,” polyQ-stretches are best known for their role in neurodegenerative diseases like Huntington’s disease, wherein the elongation of the polyQ-stretch causes proteins to clump together, leading to neuronal death and neurodegeneration. In their study, the researchers found that deleting the polyQ-stretch impairs MN1’s ability to over-stabilize the BAF complex binding to DNA, thus allowing blood cells to differentiate normally.

“What’s exciting about this research is its potentially broad implications,” said Bernt, senior author of the paper, which was published in Molecular Cell. “This is a look at how cancer can happen beyond overactive signaling and DNA damage.”

Studies building on these results, which will aim to turn this discovery into a therapy, are supported by grants awarded  from Cookies for Kids Cancer and the Children’s Cancer Research Fund.

Contact: Jennifer Lee, The Children’s Hospital of Philadelphia, 267-426-6084 or leej41@email.chop.edu

Young boy smiling outside

Get a Second Opinion

Our experts are here to review your child’s diagnosis and treatment plan, and work with primary oncologists as needed.

Oncology patient with Mom

Patient-Family Education

Review educational information for individuals and families facing childhood cancer.